These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
496 related articles for article (PubMed ID: 31237525)
1. Fingolimod Improves the Outcome of Experimental Graves' Disease and Associated Orbitopathy by Modulating the Autoimmune Response to the Thyroid-Stimulating Hormone Receptor. Plöhn S; Hose M; Schlüter A; Michel L; Diaz-Cano S; Hendgen-Cotta UB; Banga JP; Bechrakis NE; Hansen W; Eckstein A; Berchner-Pfannschmidt U Thyroid; 2019 Sep; 29(9):1286-1301. PubMed ID: 31237525 [TBL] [Abstract][Full Text] [Related]
2. An Early Wave of Macrophage Infiltration Intertwined with Antigen-Specific Proinflammatory T Cells and Browning of Adipose Tissue Characterizes the Onset of Orbital Inflammation in a Mouse Model of Graves' Orbitopathy. Philipp S; Horstmann M; Hose M; Daser A; Görtz GE; Jesenek C; Flögel U; Hansen W; Bechrakis N; Banga JPS; Eckstein A; Berchner-Pfannschmidt U Thyroid; 2022 Mar; 32(3):283-293. PubMed ID: 34779257 [No Abstract] [Full Text] [Related]
3. Genetic immunization with mouse thyrotrophin hormone receptor plasmid breaks self-tolerance for a murine model of autoimmune thyroid disease and Graves' orbitopathy. Schlüter A; Horstmann M; Diaz-Cano S; Plöhn S; Stähr K; Mattheis S; Oeverhaus M; Lang S; Flögel U; Berchner-Pfannschmidt U; Eckstein A; Banga JP Clin Exp Immunol; 2018 Mar; 191(3):255-267. PubMed ID: 29058307 [TBL] [Abstract][Full Text] [Related]
4. A Promising Mouse Model of Graves' Orbitopathy Induced by Adenovirus Expressing Thyrotropin Receptor A Subunit. Zhang M; Ding X; Wu LP; He MQ; Chen ZY; Shi BY; Wang Y Thyroid; 2021 Apr; 31(4):638-648. PubMed ID: 33076782 [No Abstract] [Full Text] [Related]
5. A cyclic peptide significantly improves thyroid function, thyrotropin-receptor antibodies and orbital mucine /collagen content in a long-term Graves' disease mouse model. Diana T; Ungerer M; Wüster C; Faßbender J; Li Z; Reimann A; Holthoff HP; Kanitz M; Kahaly GJ J Autoimmun; 2021 Aug; 122():102666. PubMed ID: 34144327 [TBL] [Abstract][Full Text] [Related]
6. Modulating gut microbiota in a mouse model of Graves' orbitopathy and its impact on induced disease. Moshkelgosha S; Verhasselt HL; Masetti G; Covelli D; Biscarini F; Horstmann M; Daser A; Westendorf AM; Jesenek C; Philipp S; Diaz-Cano S; Banga JP; Michael D; Plummer S; Marchesi JR; Eckstein A; Ludgate M; Berchner-Pfannschmidt U; Microbiome; 2021 Feb; 9(1):45. PubMed ID: 33593429 [TBL] [Abstract][Full Text] [Related]
7. Gut microbiota in experimental murine model of Graves' orbitopathy established in different environments may modulate clinical presentation of disease. Masetti G; Moshkelgosha S; Köhling HL; Covelli D; Banga JP; Berchner-Pfannschmidt U; Horstmann M; Diaz-Cano S; Goertz GE; Plummer S; Eckstein A; Ludgate M; Biscarini F; Marchesi JR; Microbiome; 2018 May; 6(1):97. PubMed ID: 29801507 [TBL] [Abstract][Full Text] [Related]
8. Linsitinib, an IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease. Gulbins A; Horstmann M; Daser A; Flögel U; Oeverhaus M; Bechrakis NE; Banga JP; Keitsch S; Wilker B; Krause G; Hammer GD; Spencer AG; Zeidan R; Eckstein A; Philipp S; Görtz GE Front Endocrinol (Lausanne); 2023; 14():1211473. PubMed ID: 37435490 [TBL] [Abstract][Full Text] [Related]
9. CD8+CD122+ T cells, a newly identified regulatory T subset, negatively regulate Graves' hyperthyroidism in a murine model. Saitoh O; Abiru N; Nakahara M; Nagayama Y Endocrinology; 2007 Dec; 148(12):6040-6. PubMed ID: 17823258 [TBL] [Abstract][Full Text] [Related]
10. The link between Graves' disease and Hashimoto's thyroiditis: a role for regulatory T cells. McLachlan SM; Nagayama Y; Pichurin PN; Mizutori Y; Chen CR; Misharin A; Aliesky HA; Rapoport B Endocrinology; 2007 Dec; 148(12):5724-33. PubMed ID: 17823263 [TBL] [Abstract][Full Text] [Related]
11. Current insights into animal models of Graves' disease and orbitopathy. Wiesweg B; Johnson KT; Eckstein AK; Berchner-Pfannschmidt U Horm Metab Res; 2013 Aug; 45(8):549-55. PubMed ID: 23613015 [TBL] [Abstract][Full Text] [Related]
12. Thyrotropin Receptor-Specific Lymphocytes in Adenovirus-TSHR-Immunized Native and Human Leukocyte Antigen-DR3-Transgenic Mice and in Graves' Disease Patient Blood. Degen H; Gavvovidis I; Blankenstein T; Uhland K; Ungerer M Thyroid; 2021 Jun; 31(6):950-963. PubMed ID: 33208049 [No Abstract] [Full Text] [Related]
13. Mouse model of Graves' orbitopathy induced by the immunization with TSHR A and IGF-1R α subunit gene. Wu R; Li N; Wang X; Wang S; Tan J; Wang R; Zheng W J Endocrinol Invest; 2024 Oct; 47(10):2507-2519. PubMed ID: 38662129 [TBL] [Abstract][Full Text] [Related]
14. Blocking the Thyrotropin Receptor with K1-70 in a Patient with Follicular Thyroid Cancer, Graves' Disease, and Graves' Ophthalmopathy. Ryder M; Wentworth M; Algeciras-Schimnich A; Morris JC; Garrity J; Sanders J; Young S; Sanders P; Furmaniak J; Rees Smith B Thyroid; 2021 Oct; 31(10):1597-1602. PubMed ID: 34114495 [No Abstract] [Full Text] [Related]
15. Cre-loxP System-Based Mouse Model for Investigating Graves' Disease and Associated Orbitopathy. Bao Y; Kim D; Cho YH; Ku CR; Yoon JS; Lee EJ Thyroid; 2023 Nov; 33(11):1358-1367. PubMed ID: 37624749 [No Abstract] [Full Text] [Related]
16. Comparative Assessment of Female Mouse Model of Graves' Orbitopathy Under Different Environments, Accompanied by Proinflammatory Cytokine and T-Cell Responses to Thyrotropin Hormone Receptor Antigen. Berchner-Pfannschmidt U; Moshkelgosha S; Diaz-Cano S; Edelmann B; Görtz GE; Horstmann M; Noble A; Hansen W; Eckstein A; Banga JP Endocrinology; 2016 Apr; 157(4):1673-82. PubMed ID: 26872090 [TBL] [Abstract][Full Text] [Related]
17. Potential involvement of the bone marrow in experimental Graves' disease and thyroid eye disease. Gulbins A; Horstmann M; Keitsch S; Soddemann M; Wilker B; Wilson GC; Zeidan R; Hammer GD; Daser A; Bechrakis NE; Görtz GE; Eckstein A Front Endocrinol (Lausanne); 2023; 14():1252727. PubMed ID: 37810891 [TBL] [Abstract][Full Text] [Related]
18. PDGF enhances orbital fibroblast responses to TSHR stimulating autoantibodies in Graves' ophthalmopathy patients. van Steensel L; Hooijkaas H; Paridaens D; van den Bosch WA; Kuijpers RW; Drexhage HA; van Hagen PM; Dik WA J Clin Endocrinol Metab; 2012 Jun; 97(6):E944-53. PubMed ID: 22438231 [TBL] [Abstract][Full Text] [Related]
19. The Role of the Microbiota in Graves' Disease and Graves' Orbitopathy. Hou J; Tang Y; Chen Y; Chen D Front Cell Infect Microbiol; 2021; 11():739707. PubMed ID: 35004341 [TBL] [Abstract][Full Text] [Related]
20. A New Highly Thyrotropin Receptor-Selective Small-Molecule Antagonist with Potential for the Treatment of Graves' Orbitopathy. Marcinkowski P; Hoyer I; Specker E; Furkert J; Rutz C; Neuenschwander M; Sobottka S; Sun H; Nazare M; Berchner-Pfannschmidt U; von Kries JP; Eckstein A; Schülein R; Krause G Thyroid; 2019 Jan; 29(1):111-123. PubMed ID: 30351237 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]